Literature DB >> 28211512

Physiology and role of irisin in glucose homeostasis.

Nikolaos Perakakis1, Georgios A Triantafyllou1, José Manuel Fernández-Real2,3, Joo Young Huh4, Kyung Hee Park5, Jochen Seufert6, Christos S Mantzoros1,7.   

Abstract

Irisin is a myokine that leads to increased energy expenditure by stimulating the 'browning' of white adipose tissue. In the first description of this hormone, increased levels of circulating irisin, which is cleaved from its precursor fibronectin type III domain-containing protein 5, were associated with improved glucose homeostasis by reducing insulin resistance. Consequently, several studies attempted to characterize the role of irisin in glucose regulation, but contradictory results have been reported, and even the existence of this hormone has been questioned. In this Review, we present the current knowledge on the physiology of irisin and its role in glucose homeostasis. We describe the mechanisms involved in the synthesis, secretion, circulation and regulation of irisin, and the controversies regarding the measurement of irisin. We also discuss the direct effects of irisin on glucose regulatory mechanisms in different organs, the indirect effects and interactions with other hormones, and the important open questions with regard to irisin in those organs. Finally, we present the results from animal interventional studies and from human clinical studies investigating the association of irisin with obesity, insulin resistance, type 2 diabetes mellitus and the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28211512      PMCID: PMC5878942          DOI: 10.1038/nrendo.2016.221

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  138 in total

1.  Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway.

Authors:  Fang Han; Shuxian Zhang; Ningning Hou; Di Wang; Xiaodong Sun
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-14       Impact factor: 4.733

2.  Irisin as an early marker for predicting gestational diabetes mellitus: a prospective study.

Authors:  Onur Erol; Neslihan Erkal; Hamit Yaşar Ellidağ; Bekir Sıtkı İsenlik; Özgür Aydın; Aysel Uysal Derbent; Necat Yılmaz
Journal:  J Matern Fetal Neonatal Med       Date:  2016-02-26

3.  Association between circulating irisin and insulin resistance in non-diabetic adults: A meta-analysis.

Authors:  Shanhu Qiu; Xue Cai; Han Yin; Martina Zügel; Zilin Sun; Jürgen Michael Steinacker; Uwe Schumann
Journal:  Metabolism       Date:  2016-02-16       Impact factor: 8.694

4.  Lower circulating irisin is associated with type 2 diabetes mellitus.

Authors:  Jian-Jun Liu; Melvin D S Wong; Wan Ching Toy; Clara S H Tan; Sylvia Liu; Xiao Wei Ng; Subramaniam Tavintharan; Chee Fang Sum; Su Chi Lim
Journal:  J Diabetes Complications       Date:  2013-04-22       Impact factor: 2.852

5.  Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Zacharias G Saridakis; Georgios Kynigopoulos; Elpida C Skouvaklidou; Dimitrios Molyvas; Maria F Vasiloglou; Aggeliki Apostolou; Thomai Karagiozoglou-Lampoudi; Aikaterina Siopi; Vassilis Mougios; Panagiotis Chatzistavridis; Grigorios Panagiotou; Andreas Filippaios; Sideris Delaroudis; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2014-06-10       Impact factor: 5.958

6.  Irisin Is Regulated by CAR in Liver and Is a Mediator of Hepatic Glucose and Lipid Metabolism.

Authors:  Li Mo; Jing Shen; Qinhui Liu; Yuwei Zhang; Jiangying Kuang; Shiyun Pu; Shihai Cheng; Min Zou; Wei Jiang; Changtao Jiang; Aijuan Qu; Jinhan He
Journal:  Mol Endocrinol       Date:  2016-03-23

7.  Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects.

Authors:  María Moreno; José María Moreno-Navarrete; Marta Serrano; Francisco Ortega; Elías Delgado; Cecilia Sanchez-Ragnarsson; Sergio Valdés; Patricia Botas; Wifredo Ricart; José Manuel Fernández-Real
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

8.  Association of serum irisin and body composition with chronic kidney disease in obese Chinese adults: a cross-sectional study.

Authors:  Shuyu Yang; Fangsen Xiao; Lingling Pan; Huijie Zhang; Zhimin Ma; Suhuan Liu; Yongwen Liu; Wei Zhang; Xin Zeng; Changqin Liu; Xiaoying Li; Xuejun Li; Zhibin Li
Journal:  BMC Nephrol       Date:  2015-02-11       Impact factor: 2.388

9.  FNDC5/irisin is not only a myokine but also an adipokine.

Authors:  Arturo Roca-Rivada; Cecilia Castelao; Lucía L Senin; María O Landrove; Javier Baltar; Ana Belén Crujeiras; Luisa María Seoane; Felipe F Casanueva; María Pardo
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

10.  Circulating Levels of Betatrophin and Irisin Are Not Associated with Pancreatic β-Cell Function in Previously Diagnosed Type 2 Diabetes Mellitus Patients.

Authors:  Lingshu Wang; Jun Song; Chuan Wang; Peng Lin; Kai Liang; Yu Sun; Tianyi He; Wenjuan Li; Ruxing Zhao; Jun Qin; Yiran Lu; Jinbo Liu; Fuqiang Liu; Xinguo Hou; Li Chen
Journal:  J Diabetes Res       Date:  2015-11-16       Impact factor: 4.011

View more
  139 in total

1.  "Remote" myokine protects from pulmonary ischemia/reperfusion injury by a surprising "proximal" control mechanism.

Authors:  Jürgen Bernhagen
Journal:  Ann Transl Med       Date:  2018-07

2.  The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women.

Authors:  Hye-Sun Park; Hyun Chang Kim; Dongdong Zhang; Hyungseon Yeom; Sung-Kil Lim
Journal:  Endocrine       Date:  2018-12-20       Impact factor: 3.633

3.  Impacts of rat hindlimb Fndc5/irisin overexpression on muscle and adipose tissue metabolism.

Authors:  W Farrash; M Brook; H Crossland; B E Phillips; J Cegielski; D J Wilkinson; D Constantin-Teodosiu; P L Greenhaff; K Smith; M Cleasby; P J Atherton
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-05-05       Impact factor: 4.310

4.  Role of irisin in effects of chronic exercise on muscle and bone in ovariectomized mice.

Authors:  Naoyuki Kawao; Shunki Iemura; Miku Kawaguchi; Yuya Mizukami; Yoshimasa Takafuji; Hiroshi Kaji
Journal:  J Bone Miner Metab       Date:  2021-02-10       Impact factor: 2.626

Review 5.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

6.  Irisin protects mitochondria function during pulmonary ischemia/reperfusion injury.

Authors:  Ken Chen; Zaicheng Xu; Yukai Liu; Zhen Wang; Yu Li; Xuefei Xu; Caiyu Chen; Tianyang Xia; Qiao Liao; Yonggang Yao; Cindy Zeng; Duofen He; Yongjian Yang; Tao Tan; Jianxun Yi; Jingsong Zhou; Hua Zhu; Jianjie Ma; Chunyu Zeng
Journal:  Sci Transl Med       Date:  2017-11-29       Impact factor: 17.956

7.  Circadian Rhythm, Exercise, and Heart.

Authors:  Chao-Yung Wang
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

Review 8.  Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output.

Authors:  Giovanni Lombardi; Veronica Sansoni; Giuseppe Banfi
Journal:  Ann Transl Med       Date:  2017-08

Review 9.  A role for FNDC5/Irisin in the beneficial effects of exercise on the brain and in neurodegenerative diseases.

Authors:  Michael F Young; Sophia Valaris; Christiane D Wrann
Journal:  Prog Cardiovasc Dis       Date:  2019-03-04       Impact factor: 8.194

10.  Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors.

Authors:  Hyeonwoo Kim; Christiane D Wrann; Mark Jedrychowski; Sara Vidoni; Yukiko Kitase; Kenichi Nagano; Chenhe Zhou; Joshua Chou; Virginia-Jeni A Parkman; Scott J Novick; Timothy S Strutzenberg; Bruce D Pascal; Phuong T Le; Daniel J Brooks; Alexander M Roche; Kaitlyn K Gerber; Laura Mattheis; Wenjing Chen; Hua Tu; Mary L Bouxsein; Patrick R Griffin; Roland Baron; Clifford J Rosen; Lynda F Bonewald; Bruce M Spiegelman
Journal:  Cell       Date:  2018-12-13       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.